Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb;23(2):150-152.
doi: 10.1016/S1473-3099(22)00834-9. Epub 2023 Jan 11.

7-month duration of SARS-CoV-2 mucosal immunoglobulin-A responses and protection

Ulrika Marking  1 , Oscar Bladh  1 , Sebastian Havervall  1 , Julia Svensson  2 , Nina Greilert-Norin  1 , Katherina Aguilera  1 , Martha Kihlgren  1 , Ann-Cristin Salomonsson  1 , Maja Månsson  1 , Radiosa Gallini  3 , Cecilia Kriegholm  3 , Philip Bacchus  4 , Sophia Hober  5 , Max Gordon  1 , Kim Blom  6 , Anna Smed-Sörensen  2 , Mikael Åberg  3 , Jonas Klingström  7 , Charlotte Thålin  8
Affiliations

7-month duration of SARS-CoV-2 mucosal immunoglobulin-A responses and protection

Ulrika Marking et al. Lancet Infect Dis. 2023 Feb.
No abstract available

PubMed Disclaimer

Conflict of interest statement

We declare no competing interests.

Figures

Figure
Figure
Duration and protection by mucosal immune responses (A) the cumulative incidence of BA.1, BA.2, and BA.5 breakthrough infection over the 8-month follow-up period, stratified on baseline (ie, 5 weeks after third vaccine dose) M-IgA concentrations above or below the 75th percentile. HRs from Cox regression model. (B) Individual M-IgA concentrations 7 months after BA.1 or BA.2 breakthrough infection in 53 individuals that became infected with BA.1 or BA.2 early during the study period. 119 individuals without breakthrough infection 8 months after third vaccine dose and eight pre-pandemic samples are shown as reference. The horizontal green dashed line indicates the cut-off level (mean + 3SD of pre-pandemic samples) and the horizontal grey dashed line indicates the upper 75th percentile of all samples at baseline (ie, the M-IgA concentration associated with protection against BA.1 or BA.2 breakthrough infection). Percentages on top of each column indicate the proportion of study participants with M-IgA concentrations remaining above the upper 75th percentile of all samples at baseline (ie, the concentration associated with protection against BA.1 or BA.2 breakthrough infection). Black horizontal lines represent median and IQR. (C) Median with IQR of M-IgA concentrations over the 7-month follow-up after BA.1 or BA.2 breakthrough infection in individuals with (red lines) and without (dashed red lines) previous WT or delta infection. Individuals without breakthrough infection are shown as reference. The horizontal green dashed line indicates the cut-off level (mean + 3 standard deviation of pre-pandemic samples) and the horizontal grey dashed line indicates the upper 75th percentile of all samples at baseline (ie, the M-IgA concentration associated with 65% protection against BA.1 or BA.2 breakthrough infection). (D) the cumulative incidence of BA.5 breakthrough infection over a 10-week period with BA.5 dominance in triple-vaccinated health-care workers with and without previous BA.1 or BA.2 infection. HRs from Cox regression model. HR=hazard ratio.
See this image and copyright information in PMC

References

    1. Focosi D, Maggi F, Casadevall A. Mucosal vaccines, sterilizing immunity, and the future of SARS-CoV-2 virulence. Viruses. 2022;14:187. - PMC - PubMed
    1. Havervall S, Marking U, Svensson J, et al. Anti-spike mucosal IgA protection against SARS-CoV-2 omicron infection. N Engl J Med. 2022;387:1333–1336. - PMC - PubMed
    1. Gilboa M, Regev-Yochay G, Mandelboim M, et al. Durability of immune response after COVID-19 booster vaccination and association with COVID-19 omicron infection. JAMA Netw Open. 2022;5:e2231778. e2231778. - PMC - PubMed
    1. Blom K, Marking U, Havervall S, et al. Immune responses after omicron infection in triple-vaccinated health-care workers with and without previous SARS-CoV-2 infection. Lancet Infect Dis. 2022;22:943–945. - PMC - PubMed
    1. Reynolds CJ, Pade C, Gibbons JM, et al. Immune boosting by B.1.1.529 (omicron) depends on previous SARS-CoV-2 exposure. Science. 2022;377 - PMC - PubMed